MONOTRATE 20 TABLETS

Indications

• Pediatric dosing adjustments
• Intravenous therapy
• Intramuscular injections
• Topical applications
• Oral medications for easier swallowing

Dosage

Children: Refer to the BNF for Children for appropriate dosing adjustments based on age and weight.

Adults: Refer to specific drug guidelines for appropriate dilution and dosage based on the active ingredient.

Mechanism of action

The mechanism of action of a diluted drug depends on the specific active ingredient within the solution. Generally, when a drug is diluted, its pharmacological effects are proportional to its concentration. The active molecules interact with specific receptors or enzymes in the body, leading to a desired therapeutic effect. For example, an analgesic diluted for oral administration will still bind to pain receptors, albeit at a lower intensity compared to its concentrated form.

Pharmacodynamics

Pharmacodynamics refers to the relationship between drug concentration and its effect on the body. In diluted solutions, the pharmacodynamic properties of the active ingredient remain intact, though the therapeutic effect may be reduced due to the lower concentration. The efficacy of the drug is influenced by factors such as receptor affinity, intrinsic activity, and the presence of other substances in the formulation.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion (ADME) of drugs. For diluted drugs, absorption can be affected by the dilution medium, which may enhance or delay the onset of action. Distribution is generally influenced by the volume of distribution of the active ingredient. Metabolism occurs primarily in the liver, where the drug is biotransformed, and excretion is typically via the kidneys. The pharmacokinetic profile may differ based on the dilution level and formulation.

Pregnancy

Consult a healthcare provider, as the effects of diluted preparations can vary depending on the active ingredient.

Breast-feeding

Consult a healthcare provider, as the safety of diluted preparations during breastfeeding can depend on the active ingredient.

Storage

Store in a cool, dry place away from direct sunlight. Ensure that the specific active ingredient's storage requirements are followed.

Indications

• Angina pectoris
• Heart failure
• Hypertension
• Intraocular pressure management

Dosage

Children: Refer to BNF for Children for specific dosing recommendations for paediatric patients.

Adults: Refer to BNF for specific dosing recommendations based on individual patient needs and clinical indications.

Mechanism of action

Isosorbide causes vascular relaxation, reducing systolic ophthalmic artery pressure (SOAP) and systolic ocular perfusion pressure (SOPP). This mechanism contributes to its effectiveness in treating conditions characterized by elevated intraocular pressure.

Pharmacodynamics

Isosorbide reduces intraocular pressure through its effects on ocular blood vessels. While in the blood, isosorbide promotes the redistribution of water toward the circulation, which enhances urinary excretion. This diuretic effect can help alleviate symptoms related to fluid overload in certain cardiovascular conditions.

Pharmacokinetics

Isosorbide is absorbed well from the gastrointestinal tract with peak plasma concentrations occurring within 1 to 2 hours after oral administration. It undergoes extensive first-pass metabolism, which significantly reduces its bioavailability. The drug is primarily eliminated through the kidneys, with a half-life ranging from 5 to 6 hours, but this may vary based on formulation and patient factors.

Indications

• Cancer (various types)
• Rheumatoid arthritis
• Multiple sclerosis
• Inflammatory bowel disease
• Psoriasis
• Hypercholesterolemia
• Infectious diseases (e.g., COVID-19)

Dosage

Children: Refer to the BNF for Children for paediatric dosing information, as it varies based on the specific monoclonal antibody and the condition being treated.

Adults: Refer to the specific monoclonal antibody product information for adult dosage, as it varies based on indication and specific agent used.

Mechanism of action

Monoclonal antibodies work by binding to specific proteins on the surface of cells. This binding can block the activity of certain proteins, mark cells for destruction by the immune system, or deliver cytotoxic agents directly to target cells. The mechanism of action varies depending on the specific monoclonal antibody but often involves modulation of immune response, inhibition of cell proliferation, and induction of apoptotic pathways.

Pharmacodynamics

The pharmacodynamics of monoclonal antibodies is primarily characterized by their specificity and affinity for targeted antigens. This leads to a variety of effects, including neutralization of pathogens, blockade of receptor-ligand interactions, and antibody-dependent cellular cytotoxicity. The clinical effects depend on the disease being treated and the specific antibody's action, such as inducing tumor regression in cancer or reducing inflammation in autoimmune diseases.

Pharmacokinetics

Monoclonal antibodies typically have a long half-life, allowing for less frequent dosing. They are generally administered intravenously or subcutaneously, with absorption and distribution influenced by the antibody's size and charge. The elimination occurs primarily through proteolytic degradation and intracellular recycling. Factors such as patient-specific variables, including immunogenicity and the presence of antibodies against the monoclonal antibody, can impact pharmacokinetics.

Interactions

• abatacept+monoclonalantibodies: Severe (increases risk of generalised infection (possibly life-threatening))
• anakinra+monoclonalantibodies: Severe (increases risk of generalised infection (possibly life-threatening))
• anthracyclines+monoclonalantibodies: Severe (increases risk of cardiotoxicity)
• filgotinib+monoclonalantibodies: Severe (increases risk of immunosuppression)
• monoclonalantibodies+fingolimod: Severe (increases risk of generalised infection (possibly life-threatening))
• normal immunoglobulin+monoclonalantibodies: Severe (affects effects)
• monoclonalantibodies+ozanimod: Severe (increases risk of generalised infection (possibly life-threatening))
• monoclonalantibodies+siponimod: Severe (increases risk of generalised infection (possibly life-threatening))
• monoclonalantibodies+vemurafenib: Severe (increases risk of hepatotoxicity)
• monoclonalantibodies+aminophylline: Moderate (decreases exposure)

Indications

• Angina pectoris
• Chronic stable angina
• Angina due to coronary artery disease

Dosage

Children: Refer to the appropriate prescribing guidelines and consult clinical references for paediatric dosing recommendations.

Adults: Refer to the appropriate prescribing guidelines and consult clinical references for specific adult dosing recommendations.

Mechanism of action

Isosorbide mononitrate is converted to nitric oxide (NO) in the body, which activates guanylate cyclase. This leads to an increase in cyclic guanosine monophosphate (cGMP) levels in smooth muscle cells, resulting in smooth muscle relaxation and vasodilation. This vasodilatory effect decreases preload and afterload on the heart, reducing myocardial oxygen demand and relieving symptoms of angina.

Pharmacodynamics

Mononitrate demonstrates a dose-dependent reduction in myocardial oxygen consumption by decreasing both venous return (preload) and systemic vascular resistance (afterload). It also facilitates coronary artery dilation, improving blood flow to ischemic myocardial tissue. The onset of action can be within 30 minutes, with peak effects generally occurring 1-2 hours after administration. The effects can last for 6-8 hours, depending on the dosing schedule.

Pharmacokinetics

Isosorbide mononitrate is well absorbed from the gastrointestinal tract, with a bioavailability of approximately 100% due to its oral formulation. It undergoes minimal first-pass metabolism. The peak plasma concentration is reached within 1-2 hours post-ingestion. The drug has a half-life of approximately 5 hours, and it is primarily eliminated via the kidneys as unchanged drug and metabolites. Steady-state concentrations are typically achieved within 24 hours of regular dosing.

Contra-indications

• Hypersensitivity to mononitrate or any of its components
• Severe hypotension
• Cardiogenic shock
• Severe anemia
• Concurrent use with phosphodiesterase inhibitors (e.g. sildenafil) due to risk of severe hypotension

Adverse effects

• Headache
• Dizziness
• Hypotension
• Flushing
• Tachycardia
• Palpitations
• Nausea
• Vomiting

Interactions

• Nitrates may enhance the effects of other antihypertensive agents
• Use with caution with alcohol, as it may exacerbate hypotensive effects
• Interactions may occur with phosphodiesterase type 5 inhibitors (e.g. sildenafil) leading to severe hypotension

Precautions

• Caution in patients with recent myocardial infarction or congestive heart failure
• Use with caution in patients with hepatic or renal impairment
• Monitor blood pressure regularly during treatment
• Consider tolerance development with long-term use

Pregnancy

Limited data available on the use of mononitrate in pregnancy. It should only be used if clearly needed and the benefits outweigh the risks.

Breast-feeding

Limited data available. Consider the benefits of breastfeeding against the need for the medication.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Extended-release tablets
• Sustained-release capsules
• Oral tablets

Mechanism of action

Isosorbide causes vascular relaxation, reducing systolic ophthalmic artery pressure (SOAP), systolic ocular perfusion pressure (SOPP).

Pharmacodynamics

Isosorbide reduces intraocular pressure through its effects on ocular blood vessels. While in the blood, isosorbide promotes redistribution of water toward the circulation, promoting the excretion of urine.